Clinical Effect Of Cross Titration Of Antipsychotics With Ziprasidone In Schizophrenia Or Schizoaffective Disorder

Viatris

Status and phase: Completed; Phase 4

Conditions: Psychotic Disorders; Schizophrenia

Treatments: Drug: ziprasidone

Study type: Interventional

Funder types: Industry

Identifiers

NCT00137020

A1281117

Details and patient eligibility

About

The primary objective is to compare effectiveness of ziprasidone treatment to current treatments (haloperidol, olanzapine or risperidone) measured by change in Brief Psychiatric Rating Scale (BPRS) scores versus baseline

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Primary diagnosis of schizophrenia or schizoaffective disorder, using DSM-IV criteria.
• Currently receiving either haloperidol, olanzapine or risperidone within -/+ 25% of the recommended daily dose (as delineated by the medication's package insert

Exclusion criteria

• Resistance to conventional antipsychotic drugs
• With antipsychotic agents other than olanzapine, risperidone or haloperidol at start of treatment regimen within 12 hours prior to first dose of study drug

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)